Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | MANBA | O00462 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL15069810 | 1.00 | LMNA (0.33) | LMNAGBA1CA1CA9MEN1 | |
| Ethylene Glycol SCHEMBL277666 | 1.00 | LMNA (0.33) | LMNAGBA1CA1CA9MEN1 | |
| Alcohol SCHEMBL9222989 | 0.89 | LMNA (0.33) | LMNAGBA1CA1CA9MEN1 | |
| SCHEMBL15034 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL439067 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL44996 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8104271 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2860232 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15195848 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL732959 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361271-A1 | PEPTIDE AGONIST | THE UNIVERSITY OF BIRMINGHAM (GB) | 2025-11-27 | — | — | US | claimed |
| EP-4652179-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-11-26 | — | — | EP | claimed |
| WO-2025226506-A1 | MONO- AND DUAL-AGONIST COMPOUNDS OF HUMAN GLP1R AND GIPR FOR OBESITY & T2DM | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4561604-A1 | PEPTIDE AGONIST | The University Of Birmingham (GB) | 2025-06-04 | — | — | EP | claimed |
| EP-4536683-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | Protagonist Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119530282-A | Method for realizing genome large fragment inversion editing based on guide editing system | 中国农业大学 | 2025-02-28 | — | — | CN | claimed |
| WO-2025038902-A2 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4472996-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| WO-2024155553-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-25 | — | — | WO | claimed |
| EP-4314828-A1 | METHODS FOR ENHANCING SPECIFICITY AND SENSITIVITY OF GROUP A STREPTOCOCCUS IMMUNOASSAY | Becton, Dickinson and Company (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023240077-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| CN-116731882-A | Method for improving expression quantity of recombinant protein in trichoderma reesei | 江南大学 | 2023-09-12 | — | — | CN | claimed |
| WO-2023150630-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| EP-4188412-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022236022-A2 | PEPTIDES AND METHODS FOR DETECTING EGG ALLERGIES | AllerGenis LLC (US) | 2022-11-10 | — | — | WO | claimed |
| WO-2022212698-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022212714-A1 | METHODS FOR ENHANCING SPECIFICITY AND SENSITIVITY OF GROUP A STREPTOCOCCUS IMMUNOASSAY | BECTON DICKINSON AND COMPANY (US) | 2022-10-06 | — | — | WO | claimed |
| EP-4041272-A1 | MOLECULAR GUIDE SYSTEM PEPTIDES AND USES THEREOF | Brown, Kathlynn, C. (US) | 2022-08-17 | — | — | EP | claimed |
| WO-2022026631-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026633-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361271-A1 | PEPTIDE AGONIST | CCL2, ACKR3, PROKR1 | LMNA 3096/4885GBA1 3126/4885CA1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.